ES2624577T3 - Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea - Google Patents

Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea Download PDF

Info

Publication number
ES2624577T3
ES2624577T3 ES12181773.8T ES12181773T ES2624577T3 ES 2624577 T3 ES2624577 T3 ES 2624577T3 ES 12181773 T ES12181773 T ES 12181773T ES 2624577 T3 ES2624577 T3 ES 2624577T3
Authority
ES
Spain
Prior art keywords
oxybutynin
clonidine
sialorrhea
agonist
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12181773.8T
Other languages
English (en)
Inventor
Alan Geoffrey Roach
Paul Goldsmith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orient Pharma (Samoa) Co Ltd
Original Assignee
Orient Pharma (Samoa) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0602855A external-priority patent/GB0602855D0/en
Priority claimed from GB0602857A external-priority patent/GB0602857D0/en
Application filed by Orient Pharma (Samoa) Co Ltd filed Critical Orient Pharma (Samoa) Co Ltd
Application granted granted Critical
Publication of ES2624577T3 publication Critical patent/ES2624577T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una formulación líquida que comprende: a) clonidina; b) oxibutinina; y c) excipientes.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES12181773.8T 2006-02-13 2007-02-12 Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea Active ES2624577T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0602857 2006-02-13
GB0602855A GB0602855D0 (en) 2006-02-13 2006-02-13 The Treatment Of Sialorrhoea
GB0602855 2006-02-13
GB0602857A GB0602857D0 (en) 2006-02-13 2006-02-13 The treatment of sialorrhoea

Publications (1)

Publication Number Publication Date
ES2624577T3 true ES2624577T3 (es) 2017-07-17

Family

ID=37944141

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07705370.0T Active ES2442694T3 (es) 2006-02-13 2007-02-12 Combinación de un agonista de los receptores alfa 2 (clonidina) y un agente antimuscarínico (oxibutinina) para el tratamiento de la sialorrea
ES12181773.8T Active ES2624577T3 (es) 2006-02-13 2007-02-12 Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES07705370.0T Active ES2442694T3 (es) 2006-02-13 2007-02-12 Combinación de un agonista de los receptores alfa 2 (clonidina) y un agente antimuscarínico (oxibutinina) para el tratamiento de la sialorrea

Country Status (12)

Country Link
US (2) US8481583B2 (es)
EP (2) EP1986642B1 (es)
JP (2) JP5296557B2 (es)
KR (1) KR101370096B1 (es)
AU (1) AU2007216320B2 (es)
CA (1) CA2642850C (es)
DK (2) DK2526943T3 (es)
ES (2) ES2442694T3 (es)
MY (1) MY145817A (es)
NZ (1) NZ570492A (es)
PT (2) PT2526943T (es)
WO (1) WO2007093824A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ570492A (en) 2006-02-13 2011-08-26 Orient Pharma Samoa Co Ltd Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
GB0715790D0 (en) * 2007-08-13 2007-09-26 Summit Corp Plc Drug combination for the treatment of sialorrhoea
US20090246256A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
US20110293535A1 (en) * 2009-02-11 2011-12-01 Heglund, A.S. Composition for buccal absorption of nicotine for the purpose of smoking cessation
SG175979A1 (en) * 2009-05-15 2011-12-29 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
WO2013090278A2 (en) 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
CA3070556A1 (en) * 2017-07-20 2019-01-24 Alan Laboratories, Inc. Compositions and methods for treatment of myopia
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
EP3888684A1 (en) * 2020-03-31 2021-10-06 Bayer Animal Health GmbH Composition having improved voluntary acceptance
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4312879A (en) * 1980-08-14 1982-01-26 Richardson-Merrell Inc. Clonidine and lofexidine as antidiarrheal agents
US5578295A (en) * 1995-04-28 1996-11-26 The Procter & Gamble Company Oral care compositions comprising certain substituted diphenyl ethers
AU1155399A (en) * 1998-06-11 1999-12-30 Arthur Janov Use of clonidine for treatment of addictions, epilepsy, sleep disorders, eating disorders and migraines
WO2001008681A1 (en) * 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
US6545046B2 (en) * 2000-08-30 2003-04-08 Theramax Inc. Method for enhanced delivery of oxybutynin and compositions thereof
MXPA05007767A (es) * 2003-01-22 2006-01-31 Pfizer Health Ab Dosis reducida de tolterodina y otros agentes antimuscarinicos para tratar trastornos urinarios.
NZ570492A (en) * 2006-02-13 2011-08-26 Orient Pharma Samoa Co Ltd Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of excess salivation or drooling
GB0611241D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production

Also Published As

Publication number Publication date
JP2013144704A (ja) 2013-07-25
PT2526943T (pt) 2017-05-22
NZ570492A (en) 2011-08-26
CA2642850A1 (en) 2007-08-23
WO2007093824A1 (en) 2007-08-23
KR101370096B1 (ko) 2014-03-04
MY145817A (en) 2012-04-30
US20090221659A1 (en) 2009-09-03
JP2009526829A (ja) 2009-07-23
EP1986642A1 (en) 2008-11-05
PT1986642E (pt) 2014-01-30
AU2007216320A1 (en) 2007-08-23
US8658683B2 (en) 2014-02-25
CA2642850C (en) 2015-06-30
EP2526943B1 (en) 2017-03-22
ES2442694T3 (es) 2014-02-12
HK1129595A1 (zh) 2009-12-04
JP5296557B2 (ja) 2013-09-25
EP1986642B1 (en) 2013-11-13
DK2526943T3 (en) 2017-05-15
EP2526943A1 (en) 2012-11-28
JP5744947B2 (ja) 2015-07-08
DK1986642T3 (da) 2014-02-03
US8481583B2 (en) 2013-07-09
KR20090019765A (ko) 2009-02-25
US20120316213A1 (en) 2012-12-13
AU2007216320B2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
ES2624577T3 (es) Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea
ES2497494T3 (es) Método de tratamiento y prevención del hiperparatiroidismo secundario
ES2483725T3 (es) Composición básica cosmética y su uso
ES2494442T3 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
ES2501591T3 (es) Composición blanqueadora con sílice fusionada
ES2477465T3 (es) Fumigantes de espinosina
ES2532948T3 (es) Composición tópica para el tratamiento de queratosis actínica
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
ES2525918T3 (es) Proceso para la fabricación de Nicorandil
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
ES2527828T3 (es) Aparato para aplicar tracción a un pene
AR088673A1 (es) Formulaciones de peliculas para los dientes
CR9626A (es) Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato
CL2011002781A1 (es) Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer.
ES2564172T3 (es) Utilización de una composición cosmética para el cuidado de las pieles grasas
ES2620754T3 (es) Uso de 5-androstano (alquil)-3,5,6-triol en la preparación de fármacos neuroprotectores
UY31406A1 (es) "producto de dispersion solida que contiene un compuesto a base de n-aril urea".
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
ES2513516T3 (es) Método para un sellado con fibrina mejorado
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
ES2609817T3 (es) Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
ES2515093T3 (es) Revestimiento de enmascarado de rayado para recipientes de vidrio